<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554462</url>
  </required_header>
  <id_info>
    <org_study_id>08033V</org_study_id>
    <nct_id>NCT01554462</nct_id>
  </id_info>
  <brief_title>The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD</brief_title>
  <official_title>The Effects of Eicosapentaenoic Acid (EPA)/ Docosahexaenoic Acid (DHA) Supplementation on Cognitive Control in Children With Attention Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forty children with and 40 children without Attention deficit Hyperactivity Disorder (ADHD)
      receive Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) or placebo via a dietary
      intervention. Cognitive control functions are measured with functional Magnetic Resonance
      Imaging (MRI) before and after the intervention. Behavioural change is monitored with
      behavioural scales.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive control task - functional MRI</measure>
    <time_frame>change over 16 week intervention period (pre/post)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioural scales: - Child Behaviour Checklist (CBCL) / Teacher Report Form (TRF) - Strengths and Weaknesses of ADHD-symptoms and Normal behaviour (SWAN) questionnaire</measure>
    <time_frame>Change over 16 week intervention period (pre/post)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acids status from cheek cells (swabs)</measure>
    <time_frame>Change over 16 week intervention period (pre/post)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ADHD active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 month intervention with EPA/DHA in ADHD group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADHD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 month dietary intervention with placebo in ADHD group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 month dietary intervention with DHA/EPA in healthy control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 month dietary intervention with placebo in healthy control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eicosapentaenoic acid / Docosahexaenoic acid</intervention_name>
    <description>650 mg EPA + 650 mg DHA daily</description>
    <arm_group_label>ADHD active</arm_group_label>
    <other_name>EPA</other_name>
    <other_name>DHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo dietary intervention (MUFA) in ADHD group</intervention_name>
    <description>Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value</description>
    <arm_group_label>ADHD Placebo</arm_group_label>
    <other_name>Mono Unsaturated Fatty Acid</other_name>
    <other_name>Poly Unsaturated Fatty Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eicosapentaenoic acid / Docosahexaenoic acid</intervention_name>
    <description>650 mg EPA and 650 mg DHA daily</description>
    <arm_group_label>Active Healthy control</arm_group_label>
    <other_name>EPA</other_name>
    <other_name>DHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo dietary intervention (MUFA) in healthy control group</intervention_name>
    <description>Placebo contains MUFA in stead of PUFA, same energy value</description>
    <arm_group_label>Healthy placebo</arm_group_label>
    <other_name>Mono Unsaturated Fatty Acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for subjects with ADHD

          1. 8-12 year old boys

          2. Diagnostic and Statistical Manual 4th edition (DSM-IV (APA, 1994)) diagnosis of ADHD,
             according to Diagnostic Interview Schedule for Children (DISC)

          3. Scores in the clinical range on the Child Behaviour Checklist (CBCL) and Teacher
             Rating Form(TRF)

          4. Ability to speak and comprehend Dutch.

          5. Used to daily consumption of margarine

        Inclusion criteria for controls

          1. 8-12 year old boys

          2. No DSM-IV (APA, 1994) diagnosis, according to DISC interview

          3. No scores in the clinical range on the Child Behaviour Checklist (CBCL) and Teacher
             Rating Form (TRF)

          4. Ability to speak and comprehend Dutch. 5 Used to daily consumption of margarine

        Exclusion Criteria:

          1. mental retardation (IQ &lt; 70)

          2. major illness of the cardiovascular, the endocrine, the pulmonary or the
             gastrointestinal system

          3. presence of metal objects in or around the body (pacemaker, dental braces)

          4. history of or present neurological disorder

          5. regular use of n-3 or n-6 fatty acid dietary supplements, products fortified with EPA
             or DHA, a regular diet high in fatty fish (= 1 serving per week) or participation in
             intervention studies or (school-) health programs in the four months prior to study
             participation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Hoeksma, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Unilever Research Vlaardingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Durston, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Utrecht University Medical Center; Child and adolescent psychiatry</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Attention</keyword>
  <keyword>Cognitive control</keyword>
  <keyword>ADHD</keyword>
  <keyword>Healthy</keyword>
  <keyword>EPA</keyword>
  <keyword>Eicosapentaenoic acid</keyword>
  <keyword>DHA</keyword>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>PUFA</keyword>
  <keyword>Omega-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

